VII international symposium on respiratory viral infections

Antiviral Therapy

Volumn 12, Issue 4 B, 2007, Pages 671-693

  Bermingham, Alison ^a   Henrickson, Kelly ^b   Hayden, Frederick ^c,d   Zambon, Maria ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

A 60444; BENZODIAZEPINE DERIVATIVE; CRX 527; DNA VACCINE; FLUDASE; HYBRID PROTEIN; IMMUNOGLOBULIN; INFLUENZA VACCINE; MOTAVIZUMAB; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NEUTRALIZING ANTIBODY; OSELTAMIVIR; PALIVIZUMAB; PLECONARIL; PROPIOLACTONE; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIBIOTIC RESISTANCE; ANTIVIRAL THERAPY; ASTHMA; AVIAN INFLUENZA; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUING EDUCATION; CONTROLLED CLINICAL TRIAL; DISEASE TRANSMISSION; HUMAN; HUMAN METAPNEUMOVIRUS; INFLUENZA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY VIRUS; RHINOVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; UNSPECIFIED SIDE EFFECT; VACCINATION; VIRAL RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VIRUS PATHOGENESIS; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; HUMANS; RESPIRATORY TRACT INFECTIONS; VIRAL VACCINES; VIRUS DISEASES; VIRUSES;

EID: 34547783897     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (106)

1. Osterhaus AD, Ellens DJ, Horzinek MC. Identification and characterization of a papillomavirus from birds (Fringillidae). Intervirology 1977; 8:351-359.
2. Osterhaus AD, Groen J, Spijkers HE, et al. Mass mortality in seals caused by a newly discovered morbillivirus. Vet Microbiol 1990; 23:343-350.
3. Fouchier RA, Schneeberger PM, Rozendaal FW, et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A 2004; 101:1356-1361.
4. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001; 7:719-724.
5. Kuiken T, Fouchier RA, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003; 362:263-270.
6. Fouchier RA, Kuiken T, Schutten M, et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 2003; 423:240.
7. Osterhaus AD, Fouchier RA, Kuiken T. The aetiology of SARS: Koch's postulates fulfilled. Philos Trans R Soc Lond B Biol Sci 2004; 359:1081-1082.
8. Haagmans BL, Kuiken T, Martina BE, et al. Pegylated interferon-a protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 2004; 10:290-293.
9. Haagmans BL, Osterhaus AD. Nonhuman primate models for SARS. PLoS Med 2006; 3:e194.
10. Pasick J, Handel K, Robinson J, et al. Intersegmental recombination between the haemagglutinin and matrix genes was responsible for the emergence of a highly pathogenic H7N3 avian influenza virus in British Columbia. J Gen Virol 2005; 86:727-731.
11. Hirst M, Astell CR, Griffith M, et al. Novel avian influenza H7N3 strain outbreak, British Columbia. Emerg Infect Dis 2004; 10:2192-2195.
12. Tweed SA, Skowronski DM, David ST, et al. Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis 2004; 10:2196-2199.
13. Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004; 350:443-450.
14. Williams JV, Crowe JE Jr, Enriquez R, et al. Human metapneumovirus infection plays an etiologic role in acute asthma exacerbations requiring hospitalization in adults. J Infect Dis 2005; 192:1149-1153.
15. Martino R, Ramila E, Rabella N, et al. Respiratory virus infections in adults with hematologic malignancies: a prospective study. Clin Infect Dis 2003; 36:1-8.
16. Williams JV, Martino R, Rabella N, et al. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. J Infect Dis 2005; 192:1061-1065.
17. Iwane MK, Edwards KM, Szilagyi PG, et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004; 113:1758-1764.
18. Kaiser L, Regamey N, Roiha H, Deffernez C, Frey U. Human coronavirus NL63 associated with lower respiratory tract symptoms in early life. Pediatr Infect Dis J 2005; 24:1015-1017.
19. van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus. Nat Med 2004; 10:368-373.
20. Fouchier RA, Hartwig NG, Bestebroer TM, et al. A previously undescribed coronavirus associated with respiratory disease in humans. Proc Natl Acad Sci U S A 2004; 101:6212-6216.
21. Russell KL, Hawks worth AW, Ryan MA, et al. Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004. Vaccine 2006; 24:2835-2842.
22. Russell KL, Broderick MP, Franklin SE, et al. Transmission dynamics and prospective environmental sampling of adenovirus in a military recruit setting. J Infect Dis 2006; 194:877-885.
23. Grenfell BT, Pybus OG, Gog JR, et al. Unifying the epidemiological and evolutionary dynamics of pathogens. Science 2004; 303:327-332.
24. Park AW, Wood JL, Daly JM, Newton JR, et al. The effects of strain heterology on the epidemiology of equine influenza in a vaccinated population. Proc Biol Sci 2004; 271:1547-1555.
25. Viboud C, Bjornstad ON, Smith DL, Simonsen L, Miller MA, Grenfell BT. Synchrony, waves, and spatial hierarchies in the spread of influenza. Science 2006; 312:447-451.
26. Kuiken T, Holmes EC, McCauley J, Rimmelzwaan GF, Williams CS, Grenfell BT. Host species barriers to influenza virus infections. Science 2006; 312:394-397.
27. Nelson MI, Simonsen L, Viboud C, et al. Stochastic processes are key determinants of short-term evolution in influenza A virus. PLoS Pathog 2006; 2:e125.
28. Dauber B, Heins G, Wolff T. The influenza B virus nonstructural NS1 protein is essential for efficient viral growth and antagonizes beta interferon induction. J Virol 2004; 78:1865-1872.
29. Donelan NR, Dauber B, Wang X, Basler CF, Wolff T, Garcia-Sastre A. The N- and C-terminal domains of the NS1 protein of influenza B virus can independently inhibit IRF-3 and β interferon promoter activation. J Virol 2004; 78:11574-11582.
30. Hoffmann E, Mahmood K, Yang CF, Webster RG, Greenberg HB, Kemble G. Rescue of influenza B virus from eight plasmids. Proc Natl Acad Sci U S A 2002; 99:11411-11416.
31. Imai M, Watanabe S, Ninomiya A, Obuchi M, Odagiri T. Influenza B virus BM2 protein is a crucial component for incorporation of viral ribonucleoprotein complex into virions during virus assembly. J Virol 2004; 78:11007-11015.
32. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 2002; 76:105-115.
33. Taubenberger JK, Reid AH, Krafft AE, Bijwaard KE, Fanning TG. Initial genetic characterization of the 1918 "Spanish" influenza virus. Science 1997; 275:1793-1796.
34. Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG. Characterization of the 1918 influenza virus polymerase genes. Nature 2005; 437:889-893.
35. Stevens J, Blixt O, Glaser L, et al. Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol 2006; 355:1143-1155.
36. Basler CF, Reid AH, Dybing JK, et al. Sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes. Proc Natl Acad Sci U S A 2001; 98:2746-2751.
37. Kuiken T, van den Hoogen BG, van Riel DA, et al. Experimental human metapneumovirus infection of cynomolgus macaques (Macaca fascicularis) results in virus replication in ciliated epithelial cells and pneumocytes with associated lesions throughout the respiratory tract. Am J Pathol 2004; 164:1893-1900.
38. van den Hoogen BG, Herfst S, de Graaf M, et al. Experimental infection of macaques with human metapneumovirus induces transient protective immunity. J Gen Virol 2007; 88:1251-1259.
39. Greenough TC, Babcock GJ, Roberts A, et al. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis 2005; 191:507-514.
40. Greenough TC, Carville A, Coderre J, et al. 2005. Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus. Am J Pathol 2005; 167:455-463.
41. DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis 2005; 191:1861-1868.
42. Chu YK, Rossi C, Leduc JW, Lee HW, Schmaljohn CS, Dalrymple JM. Serological relationships among viruses in the Hantavirus genus, family Bunyaviridae. Virology 1994; 198:196-204.
43. Nichol ST, Spiropoulou CF, Morzunov S, et al. Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. Science 1993; 262:914-917.
44. Eiken Genome Site [homepage on the internet]. Tokyo: Eiken Chemical Co. Ltd. The principle of LAMP method (ver 7.2). Available from http://loopamp. eiken.co.Jp/e/lamp/anim.html
45. Belshe RB, Mendelman PM, Treanor I, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998; 338:1405-1412.
46. Arden KE, Nissen MD, Sloots TP, Mackay IM. New human coronavirus, HCoV-NL63, associated with severe lower respiratory tract disease in Australia. J Med Virol 75:455-462.
47. Druce I, Tran T, Kelly H, et al. Laboratory diagnosis and surveillance of human respiratory viruses by PCR in Victoria, Australia, 2002-2003. J Med Virol 2005; 75:122-129.
48. Mackay IM, Bialasiewicz S, Waliuzzaman Z, et al. Use of the P gene to genotype human metapneumovirus identifies 4 viral subtypes. J Infect Dis 2004; 190:1913-1918.
49. Mackay IM, Bialasiewicz S, Jacob KC, et al. Genetic diversity of human metapneumovirus over 4 consecutive years in Australia. J Infect Dis 2006; 193:1630-1633.
50. Pickles RJ, McCarty D, Matsui H, Hart PJ, Randell SH, Boucher RC. Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. J Virol 1998; 72:6014-6023.
51. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 2002; 76:5654-5666.
52. Zhang L, Bukreyev A, Thompson CI, et al. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol 2005; 79:1113-1124.
53. Sims AC, Baric RS, Yount B, Burkett SE, Collins PL, Pickles RJ. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol 2005; 79:15511-15124.
54. Sims AC, Yount B, Burkett SE, Baric RS, Pickles RJ. SARS CoV replication and pathogenesis in human airway epithelial cultures. Adv Exp Med Biol; 2006; 581:535-538.
55. Sims AC, Burkett SE, Yount B, Pickles RJ. SARS-CoV replication and pathogenesis in an in vitro model of the human conducting airway epithelium. Virus Res 2007; doi:10.1016/j.physletb.2003.10.071 [Epub ahead of print].
56. Message SD, Johnston SL. Host defense function of the airway epithelium in health and disease: clinical background. J Leukoc Biol 2004; 75:5-17.
57. McCullers JA. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 2004; 190:519-526.
58. McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 2002; 186:341-50.
59. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 2003; 187:1000-1009.
60. Peltola VT, McCullers JA. Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr Infect Dis J 2004; 23:S87-S97.
61. Peltola VT, Murti KG, McCullers JA. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis 2005; 192:249-257.
62. Hoffjan S, Ostrovnaja I, Nicolae D, et al. Genetic variation in immunoregulatory pathways and atopic phenotypes in infancy. J Allergy Clin Immunol 2004; 113:511-518.
63. Hoffjan S, Nicolae D, Ostrovnaya I, et al. Gene-environment interaction effects on the development of immune responses in the 1st year of life. Am J Hum Genet 2005; 76:696-704.
64. Thompson CI, Barclay WS, Zambon MC, Pickles RJ. Infection of human airway epithelium by human and avian strains of influenza a virus. J Virol 2006; 80:8060-8068.
65. Subbarao EK, London W, Murphy BR. A single amino acid in the PB2 gene of influenza A virus is a determinant of host range. J Virol 1993; 67:1761-1764.
66. Koopmans M, Wilbrink B, Conyn M, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004; 363:587-593.
67. Shinya K, Hamm S, Hatta M, Ito H, Ito T, Kawaoka Y. PB2 amino acid at position 627 affects replicative efficiency, but not cell tropism, of Hong Kong H5N1 influenza A viruses in mice. Virology 2004; 320:258-266.
68. Garbino J, Gerbase MW, Wunderli W, et al. Respiratory viruses and severe lower respiratory tract complications in hospitalized patients. Chest 2004; 125:1033-1039.
69. Garbino J, Gerbase MW, Wunderli W, et al. Lower respiratory viral illnesses: improved diagnosis by molecular methods and clinical impact. Am J Respir Crit Care Med 2004; 170:1197-1203.
70. Taussig LM, Wright AL, Holberg CJ, Halonen M, Morgan WJ, Martinez FD. Tucson Children's Respiratory Study: 1980 to present. J Allergy Clin Immunol 2003; 111:661-675; quiz 676.
71. Heymann PW, Carper HT, Murphy DD, et al. Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing. J Allergy Clin Immunol 2004; 114:239-247.
72. Ravenholt RT, Foege WH. 1918 influenza, encephalitis lethargica, parkinsonism. Lancet 1982; 2:860-864.
73. Morishima T, Togashi T, Yokota S, et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis 2002; 35:512-517.
74. Togashi T, Matsuzono Y, Narita M, Morishima T. Influenza-associated acute encephalopathy in Japanese children in 1994-2002. Virus Res 2004; 103:75-78.
75. Juven T, Mertsola J, Waris M, et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J 2000; 19:293-298.
76. Peltola V, Reunanen T, Ziegler T, Silvennoinen H, Heikkinen T. 2005. Accuracy of clinical diagnosis of influenza in outpatient children. Clin Infect Dis 41:1198-1200.
77. Subbarao K, McAuliffe J, Vogel L, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 2004; 78:3572-3577.
78. McAuliffe J, Vogel L, Roberts A, et al. Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology 2004; 330:8-15.
79. Traggiai E, Becker S, Subbarao K, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS cotonavirus. Nat Med 2004; 10:871-875.
80. Subbarao K, Roberts A. Is there an ideal animal model for SARS? Trends Microbiol 2006; 14:299-303.
81. Chen H, Matsuoka Y, Chen Q, Cox NJ, Murphy BR, Subbarao K. Generation and characterization of an H9N2 cold-adapted reassortant as a vaccine candidate. Avian Dis 2003; 47:1127-1130.
82. Suguitan AL Jr, McAuliffe J, Mills KL, et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006; 3:e360.
83. Maines TR, Chen LM, Matsuoka Y, et al. Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci U S A 2006; 103:12121-12126.
84. Siber GR, Leombruno D, Leszczynski J, et al. Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis 1994; 169:1368-1373.
85. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A 2004; 101:4620-4624.
86. Chu VC, Whittaker GR. Influenza virus entry and infection require host cell N-linked glycoprotein. Proc Natl Acad Sci U S A 2004; 101:18153-18158.
87. Malakhov MP, Aschenbrenner LM, Smee DF, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50:1470-1479.
88. Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25:870-879.
89. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685-696.
90. Piedra PA, Gaglani MJ, Kozinetz CA, et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 2005; 23:1540-1548.
91. Mendelman PM, Rappaport R, Cho I, et al. Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr Infect Dis J 2004; 23:1053-1055.
92. Henderson EA, Alber DG, Baxter RC, et al. 1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate. J Med Chem 2007; 50:1685-1692.
93. Carter MC, Alber DG, Baxter RC, et al. 1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. J Med Chem 2006; 49:2311-2319.
94. McKimm-Breschkin JL, McDonald M, Blick TJ, Colman PM. Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme. Virology 1996; 225:240-242.
95. McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, et al. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother 1996; 40:40-46.
96. Hurt AC, Iannello P, Jachno K, et al. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob Agents Chemother 2006; 50:1872-1874.
97. Hayden F, Klimov A, Tashiro M, et al. Neuraminidase inhibitor susceptibility network position statement: Antivir Resistance in influenza A/H5N1 viruses. Antivir Ther 2005; 10:873-877.
98. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50:2395-2402.
99. Kaiser L, Crump CE, Hayden FG. In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antivir Res 2000; 47:215-220.
100. Pevear DC, Hayden FG, Demenczuk TM, Barone LR, McKinlay MA, Collett MS. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother 2005; 49:4492-4499.
101. Hayden FG, Herrington DT, Coats TL, et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 2003; 36:1523-1532.
102. Dimmock NJ, Beck S, McLain L. Protection of mice from lethal influenza: evidence that defective interfering virus modulates the immune response and not virus multiplication. J Gen Virol 1986; 67 Pt 5:839-850.
103. Duhaut SD, Dimmock NJ. Heterologous protection of mice from a lethal human H1N1 influenza A virus infection by H3N8 equine defective interfering virus: comparison of defective RNA sequences isolated from the DI inoculum and mouse lung. Virology 1998; 248:241-253.
104. Mann A, Marriott AC, Balasingam S, Lambkin R, Oxford JS, Dimmock NJ. Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection. Vaccine 2006; 24:4290-4296.
105. Baldridge JR, McGowan P, Evans JT, et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004; 4:1129-1138.
106. Cluff CW, Baldridge JR, Stover AG, et al. Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immun 2005; 73:3044-3052.